OtonecineCAS# 6887-34-9 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 6887-34-9 | SDF | Download SDF |
PubChem ID | 5281740 | Appearance | Powder |
Formula | C9H15NO3 | M.Wt | 185.22 |
Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (4R,6Z)-4-hydroxy-6-(hydroxymethyl)-1-methyl-2,3,4,8-tetrahydroazocin-5-one | ||
SMILES | CN1CCC(C(=O)C(=CC1)CO)O | ||
Standard InChIKey | GRAGROPQORVALZ-VKWJFSHESA-N | ||
Standard InChI | InChI=1S/C9H15NO3/c1-10-4-2-7(6-11)9(13)8(12)3-5-10/h2,8,11-12H,3-6H2,1H3/b7-2-/t8-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1.Otonecine-type PA induces hepatotoxicity, the formation of an unstable pyrrolic ester plays a key role. |
Otonecine Dilution Calculator
Otonecine Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 5.399 mL | 26.9949 mL | 53.9898 mL | 107.9797 mL | 134.9746 mL |
5 mM | 1.0798 mL | 5.399 mL | 10.798 mL | 21.5959 mL | 26.9949 mL |
10 mM | 0.5399 mL | 2.6995 mL | 5.399 mL | 10.798 mL | 13.4975 mL |
50 mM | 0.108 mL | 0.5399 mL | 1.0798 mL | 2.1596 mL | 2.6995 mL |
100 mM | 0.054 mL | 0.2699 mL | 0.5399 mL | 1.0798 mL | 1.3497 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 8-O-Methylretusin-7-O-beta-D-glucopyranoside
Catalog No.:BCN7899
CAS No.:68862-13-5
- HMP Linker
Catalog No.:BCC2832
CAS No.:68858-21-9
- Fmoc-Val-OH
Catalog No.:BCC3570
CAS No.:68858-20-8
- Boc-D-Tyr(Me)-OH
Catalog No.:BCC2597
CAS No.:68856-96-2
- Astemizole
Catalog No.:BCC7691
CAS No.:68844-77-9
- Xanthohumol L
Catalog No.:BCN8017
CAS No.:688360-15-8
- Xanthohumol I
Catalog No.:BCN8016
CAS No.:688360-06-7
- IWP 12
Catalog No.:BCC5622
CAS No.:688353-45-9
- 4-Epi-isoinuviscolide
Catalog No.:BCN4251
CAS No.:68832-39-3
- D-Prolinol(oil)
Catalog No.:BCC2708
CAS No.:68832-13-3
- Retusamine
Catalog No.:BCN2122
CAS No.:6883-16-5
- Sempervirine
Catalog No.:BCN4250
CAS No.:6882-99-1
- Eburicol
Catalog No.:BCN4252
CAS No.:6890-88-6
- Guaiacol salicylate
Catalog No.:BCC8327
CAS No.:87-16-1
- H-D-Glu-OH
Catalog No.:BCC2936
CAS No.:6893-26-1
- Kahweol
Catalog No.:BCC9006
CAS No.:6894-43-5
- SKF 91488 dihydrochloride
Catalog No.:BCC6675
CAS No.:68941-21-9
- Mulberrofuran A
Catalog No.:BCN3677
CAS No.:68978-04-1
- Uncarine A
Catalog No.:BCN7767
CAS No.:6899-73-6
- Quinacrine 2HCl
Catalog No.:BCC4709
CAS No.:69-05-6
- Chlorpromazine HCl
Catalog No.:BCC4460
CAS No.:69-09-0
- Ampicillin
Catalog No.:BCC1199
CAS No.:69-52-3
- Penicillin G Sodium
Catalog No.:BCC4638
CAS No.:69-57-8
- D-Mannitol
Catalog No.:BCN2205
CAS No.:69-65-8
Characterization of rat liver microsomal metabolites of clivorine, an hepatotoxic otonecine-type pyrrolizidine alkaloid.[Pubmed:11095586]
Drug Metab Dispos. 2000 Dec;28(12):1475-83.
The metabolism of the hepatotoxic Otonecine-type pyrrolizidine alkaloid (PA), clivorine, was investigated using rat liver microsomes. The metabolites dehydroretronecine (DHR), 7-glutathionyldehydroretronecine (7-GSH-DHR), 7, 9-diglutathionyldehydroretronecine (7,9-diGSH-DHR), and clivoric acid were identified using chromatographic and mass spectrometric analyses. NMR characterizations were also performed on the isolated clivoric acid and the synthetic 7-GSH-DHR and 7,9-diGSH-DHR. The results indicated that the two glutathione (GSH) conjugates were formed by reaction of the unstable toxic pyrrolic ester with GSH added in the microsomal incubation system, whereas DHR was generated from hydrolysis of the unstable pyrrolic ester, and that clivoric acid was produced from all these further conversions of the unstable pyrrolic ester. Furthermore, tissue-bound pyrroles were also determined to be present after microsomal incubation of clivorine. Clivoric acid has not been previously identified, and DHR and 7, 9-diGSH-DHR were found, for the first time, as metabolites of an Otonecine-type PA, while 7-GSH-DHR was previously reported by us to be a microsomal metabolite of clivorine. The in vitro metabolic pathway of clivorine was delineated to be the initial formation of the unstable pyrrolic ester, which then may undergo hydrolysis, GSH conjugations, or covalent binding with hepatic tissues that may lead to hepatotoxicity. The present definitive identification of four pyrrolic ester-related metabolites of clivorine and indirect determination of bound pyrroles provide the strongest evidence to date to support the hypothesis that the formation of an unstable pyrrolic ester plays a key role in Otonecine-type PA-induced hepatotoxicity.
Metabolic formation of DHP-derived DNA adducts from a representative otonecine type pyrrolizidine alkaloid clivorine and the extract of Ligularia hodgsonnii hook.[Pubmed:15144228]
Chem Res Toxicol. 2004 May;17(5):702-8.
Plants that contain pyrrolizidine alkaloids (PAs) are widely distributed, and PAs have been shown to be genotoxic and tumorigenic in experimental animals. Our recent mechanistic studies indicated that riddelliine, a tumorigenic retronecine type PA, induced tumors via a genotoxic mechanism mediated by the formation of a set of eight 6,7-dihydro-7-hydroxy-1-hydroxymethyl-5H-pyrrolizine (DHP)-derived DNA adducts. However, it is not known if this mechanism is general to PAs of other types. In this study, we report that the metabolism of clivorine, a tumorigenic Otonecine type PA, by F344 rat liver microsomes results in DHP formation. When incubations were conducted with clivorine in the presence of calf thymus DNA, eight DHP-derived DNA adducts were formed. The Ligularia hodgsonnii Hook plant, an antitussive traditional Chinese medicine, was found to contain Otonecine type PAs with clivorine being predominant. DHP and DHP-derived DNA adducts were also obtained when microsomal incubations were conducted with extracts of L. hodgsonnii Hook. This is the first report that DHP-derived DNA adducts are formed from the metabolic activation of Otonecine type PA and that these DHP-derived DNA adducts are potential biomarkers of PA exposure and PA-induced tumorigenicity. These results also provide evidence that the principal metabolic activation pathway of clivorine leading to liver genotoxicity and tumorigenicity is (i) formation of the corresponding dehydropyrrolizidine (pyrrolic) derivative through oxidative N-demethylation of the necine base followed by ring closure and dehydration and (ii) binding of the pyrrolic metabolite to DNA leading to the DNA adduct formation and tumor initiation.